A pharmacy that keeps compounded semaglutide or tirzepatide on hand for a physician's office, rather than compounding it against a specific patient's prescription, is operating in one of the least settled corners of compounding law. Section 503A of the Federal Food, Drug, and Cosmetic Act requires a patient-specific prescription before a compounding pharmacy or physician distributes a compounded drug, and the Food and Drug Administration (FDA) treats most non-patient-specific office-use compounding by a 503A pharmacy as beyond the reach of that authority. State boards of pharmacy do not read the question the same way. Several authorize limited office-use compounding under their own rules, with conditions that differ sharply from state to state, which means a pharmacy compliant with its home board can still be exposed under federal law, and product shipped across state lines can land in a jurisdiction with its own separate limits.
The Federal Patient-Specific Prescription Requirement
Under 503A, a compounder may distribute a compounded drug only pursuant to a valid prescription order for an identified patient. FDA's December 2016 guidance on the prescription requirement states that some state boards authorize prescriptions without an individual patient's name, but that a prescription lacking a named patient does not meet the 503A standard. Non-patient-specific compounding for hospitals, clinics, and practitioner offices is instead the province of 503B outsourcing facilities, which operate under cGMP and FDA inspection and, unlike 503A pharmacies, may distribute compounded drugs without a patient-specific prescription.
The Limited Anticipatory-Compounding Exception
503A permits a narrow form of anticipatory compounding: a pharmacist or physician may compound before receiving a prescription if the quantity is limited and grounded in an established prescribing relationship. FDA's interim compliance policy caps that inventory at a 30-day supply, calculated from the highest volume of patient-specific prescriptions the compounder actually filled for that drug in any 30-day period over the prior year, and the cap does not extend the product's beyond-use date. That exception is built for a compounder anticipating prescriptions it expects to receive. It is not a mechanism for building standing office stock, which is exactly where several state rules diverge from FDA's position.
The State Patchwork
Texas is the clearest example of a state rule that authorizes what FDA's guidance treats as a 503B function. Texas State Board of Pharmacy rules permit a Class A or Class E pharmacy to compound and deliver a reasonable quantity of a preparation to a practitioner's office for office use, provided the label reads "For Office Use Only, Not for Resale," the quantity does not exceed what the practitioner is likely to use before the beyond-use date, and separate distribution records are kept for at least two years. Other states run the opposite direction. Legal analysis from Frier Levitt describes California and Alabama restricting bulk office-use shipments into their states from non-resident pharmacies, tightening the position to patient-specific compounding only for product crossing their borders. A pharmacy that ships compounded office stock to prescribers in more than one state has to clear its home board's rule, FDA's guidance, and the receiving state's separate position, three standards that do not automatically align.
A pharmacy's own state board authorizing office-use compounding does not resolve the federal question, and the two positions can point in opposite directions on the same batch of drug.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies promptly retain experienced healthcare defense counsel upon receiving a subpoena, an FDA or state board inquiry, or any other government request touching office-use compounding. Early legal intervention can protect the pharmacy's rights, ensure appropriate responses to the inquiry, avoid inadvertent admissions about how office stock is compounded and dispensed, preserve defenses tied to state board authorization, and let counsel communicate with investigators on the pharmacy's behalf. Delaying representation can significantly affect the outcome of a matter and expose the pharmacy to unnecessary risk. Pharmacies facing a state board inquiry into their compounding records may also find State Board Compounding Inspections: Preparation and Response useful background on what an inspection actually covers.
How Health Law Alliance Can Help
Health Law Alliance advises compounding pharmacies on the intersection of 503A and 503B authority, state board of pharmacy rules on office-use and anticipatory compounding, and the defense of pharmacies facing an FDA warning letter or state board action tied to office stock. If your pharmacy compounds for office use or is evaluating whether to, contact us for a free, confidential consultation.
